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Introduction: Current treatment of CF lung disease involves a number of inhaled,
intranasal, oral and IV medications. We describe the concomitant medication (CM)
use in placebo (PL) recipients during a phase 3 trial of denufosol.
Methods: A Phase 3, multicenter, randomized, double-blind, PL-controlled trial
was conducted at 62 CF centers in N. America in CF patients (pts) who were
clinically stable on entry, 5 yrs of age and with FEV1 75% pred. Stable chronic
treatments were allowed (except hypertonic saline) and tracked at all visits. Pts
were randomized to denufosol (60mg) or PL (normal saline) inhalation TID for
24 weeks.
Results: From a total of 352 pts, 175 received PL during the 24-week double-
blind phase of the study. Among these pts, the mean age was 14.8 years. The
mean FEV1 % pred. was 92%, the mean FEF25−75 % pred. was 84%, and the
percentage of pts with P. aeruginosa in respiratory cultures was 48%. PL-treated
pts used the following classes of CMs: selective SABAs (91%), selective LABAs
(41%), mucolytics (primarily dornase alfa) (78%), chronic oral macrolides (41%),
inhaled antibiotics (54%), IV antibiotics (10%), inhaled corticosteroids (55%),
oral corticosteroids (19%), intranasal corticosteroids (58%) and oral leukotriene
modiﬁers (27%). Overall, at least 50% of PL-treated pts used at least 5 CMs for
the treatment of their CF lung disease.
Conclusion: Pts with CF face a large treatment burden. New disease modifying
treatments that address the basic defects of CF lung disease may reduce the need
for the extensive polypharmacy now addressing disease related complications.
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Introduction: Pulmonary exacerbations (PE) are a frequent event in cystic ﬁbrosis
(CF) and responsible for much of the diseases morbidity. Whereas the majority of PE
are characterized by elevated inﬂammatory markers (IM), a subset of exacerbations
diagnosed on clinical grounds present with low IM.
Objectives and Methods: To determine if there are differences in the clinical
characteristics and outcome of those PE associated with normal IM. Admission
serum C-reactive protein (CRP) measurements of 10 kg/dl were deﬁned as PE
with normal inﬂammatory markers.
Result: 237 patients were followed from 2006 to 2008 and experienced 628 episodes
of PE. Of the 131 patients who experienced exacerbations, 91 patients had 228 PE
characterized by CRP< 10. Baseline mean FEV1 (in the previous 3 months) was
higher in patient with CRP< 10 (55.3% predicted vs 47.1%, p< 0.001). CRP< 10
PE episodes were more likely to occur in individuals who chronically failed to
culture CF pathogens with risk ratio (RR) 1.84 and less likely to occur in individuals
chronically infected with B. cepacia RR0.42. CRP< 10 PE were characterized
by a less severe decline in FEV1 at admission [−6.2% vs −8.6%, p = 0.0005].
Treatment duration was shorter for CRP< 10 PE, 12.5 days vs 14.6, p = 0.002.
However, improvement of FEV1 post-treatment was lower in the CRP< 10 group,
+8.9% vs +10.9%, p = 0.01.
Conclusion: PE characterized by subjective symptoms but normal IM are common
in CF especially in those individuals with milder disease. While typically managed
with the same aggressive therapy, these interventions fail to produce the same
magnitude of improvement in lung function at treatment completion.
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Introduction: Close monitoring of CF patients is necessary to improve outcome.
For children aged 0−4 years, currently used routine lung function tests are cum-
bersome or not feasible. It is therefore important to develop alternative methods to
assess pulmonary disease. Lung Clearance Index (LCI), nightly oxygen saturation
(SpO2), and/or cough audiometry might be valuable tools in the monitoring of
CF patients.
Aim: To compare LCI, overnight SpO2 and cough in CF patients aged 0−4 years
old with a group of healthy controls.
Methods: Prospective cross sectional study. Children with CF were recruited from
the outpatient clinic. Healthy children were recruited from child day care facilities.
LCI was measured by the Exhalyzer®D at the outpatient clinic. Nightly SpO2 was
measured by the Novametrix Model 2001 MARS pulse oximeter and nightly cough
was measured with an audiometer. Both were measured at home during a normal
night sleep. We aim to complete inclusion of 20 CF patients and 30 healthy children
by April 2010.
Results: To date 38 subjects were included: 18 CF patients (mean age 2.6 yrs) and
20 healthy children (mean age 2.8 yrs). In this abstract we report preliminary data.
Age, sex, height and weight were not signiﬁcantly different between both groups.
LCI was higher in CF patients than in healthy children: mean LCI was 8.13 in
CF patients and 7.09 in healthy children (p = 0.03). For nightly oxygen saturation
and for cough no signiﬁcant differences were found in this preliminary analysis.
Conclusions: LCI showed a clear difference between healthy children and CF pa-
tients at a young age. This suggests that LCI is a sensitive test to detect pulmonary
changes at an early stage.
218* Ventilation inhomogeneity correlates with airway colonization in
patients with CF
K. Green1, N. Høiby2, P.M. Gustafsson3, T. Pressler1, K.G. Nielsen1.
1Rigshospitalet, CF-Center Copenhagen, Pediatric Pulmonary Service,
Copenhagen, Denmark; 2Rigshospitalet, Clinical Microbiology, Copenhagen,
Denmark; 3Central Hospital, Pediatrics, Sko¨vde, Sweden
Background: Lung clearance index (LCI), a measure of ventilation distribution and
small airway dysfunction derived from multiple breath inert gas washout (MBW)
detects lung damage in CF more readily than other pulmonary function tests. Thus,
previous studies have shown abnormal LCI among CF patients with chronic gram-
negative bacterial airway infection.
Methods: Cross-sectional, retrospective study. Forty-ﬁve CF patients aged 5 to
18 yrs participated in the study. LCI was derived from MBW using mass spectrom-
etry and SF6 as inert gas. Results of monthly sputum cultures the previous year
were extracted from CF-database. All were in stable condition with no signs of
exacerbation at time of test.
Results:Median FEV1 was 94% predicted (51% to 133%) and median LCI was 8.5
(6.2 to 13.7). In total 7/44 (16%) had FEV1 < 80% predicted and 37/45 (82%) had
abnormal LCI (>7.17). LCI, but not FEV1 % predicted, correlated to number of
positive respiratory cultures over the previous year (r2=0.524, p< 0.001). Patients
with frequent positive culture with S. aureus had highest LCI levels (p< 0.005),
Twelve subjects were chronically or intermittently infected with gram-negative
bacteria (S. maltophilia 4, P. aeruginosa 7 and A. xylosoxidans 1), but there was
no impact of gram-negative infection status on LCI. Furthermore, no signiﬁcant
inﬂuence on LCI by any positive airway culture on day of test was demonstrated.
Conclusion: Small airway dysfunction detected by MBW was, despite normal
spirometry, signiﬁcantly related to recurrent infection, particularly with S. aureus
in children with CF. Further studies in larger numbers are needed to assess possible
causal relationship.
